State University of New York at Buffalo — Biomedical Watch V2

Traitements10programmes

Essais5liés

Publications0liées

SourceDBlocale

Traitements

10

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.	SEP	À vérifier	À vérifier	United States	À vérifier
Lithium for Parkinson's: an Extension TrialThis study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week lithium clinical trials.	Parkinson	Phase 1/2	À vérifier	United States	À vérifier
MayzentTo assess the efficacy of Mayzent on microglia pathology in patients with active SPMS, as compared to the active control group of MS patients treated with the Ocrevus, as measured by changes in microglial activation in the lesional and non-lesional NAWM and NAGM and in the peri-plaque area of chronic lesions in the brain.	SEP	Phase 2/3		United States	À vérifier
OcrevusThe purpose of this research study is to investigate the effectiveness of MS Disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (RRMS). Cognitive fatigue is the kind of fatigue that occurs after intense mental concentration as after a session of problem solving.	SEP	Phase 2/3	Traitement symptomatique	United States	À vérifier
ORATORIO-CP — Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMSThe goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process.	SEP	À vérifier	Immunomodulation	United States	À vérifier
ORATORIO-CP — Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMSThe goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process.	SEP	À vérifier	Immunomodulation	United States	À vérifier
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.	SEP	À vérifier	À vérifier	United States	À vérifier
OcrevusThe purpose of this research study is to investigate the effectiveness of MS Disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (RRMS). Cognitive fatigue is the kind of fatigue that occurs after intense mental concentration as after a session of problem solving.	SEP	À vérifier	Traitement symptomatique	United States	À vérifier
Lithium for Parkinson's: an Extension TrialThis study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week lithium clinical trials.	Parkinson	Phase 1/2	À vérifier	United States	À vérifier
MayzentTo assess the efficacy of Mayzent on microglia pathology in patients with active SPMS, as compared to the active control group of MS patients treated with the Ocrevus, as measured by changes in microglial activation in the lesional and non-lesional NAWM and NAGM and in the peri-plaque area of chronic lesions in the brain.	SEP	Phase 2/3		United States	À vérifier

Essais cliniques

5

Molécule	Indication / population	Phase	NCT	Titre	Statut
Mayzent	SEP	Phase 2/3	NCT04925557	Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis	TERMINATED
Lithium for Parkinson's: an Extension Trial	Parkinson	Phase 1/2	NCT06592014	Lithium for Parkinson's: an Extension Trial	ENROLLING_BY_INVITATION
Ocrevus	SEP	À vérifier	NCT04448977	Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI	COMPLETED
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)	SEP	À vérifier	NCT05974839	Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)	COMPLETED
ORATORIO-CP — Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS	SEP	À vérifier	NCT05974852	ORATORIO-CP — Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.